Lacosamide Market Report 2025 (Global Edition)

Global Lacosamide Market Report 2025 Market Size Split by Type (Tablets, Oral solutions, Intravenous), by Application (Adults, Pediatric patients)

Lacosamide Market Report Description

We have various report editions of Lacosamide Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Lacosamide Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Top Companies Market Share in Lacosamide Industry: (In no particular order of Rank)

• Becton Dickinson and Company
• Agilent Technologies Inc.
• Merck & Co. Inc.
• Waters Corporation
• Abbott Laboratories
• Johnson & Johnson
• Promega Corporation
• Sino Biological Inc.
• Siemens Healthineers
• Roche Holding AG
• Bio-Rad Laboratories
• Thermo Fisher Scientific Inc UCB
• Teva
• Amneal Pharmaceuticals
• MSN Laboratories
• Alembic Pharma
• Glenmark
• Aurobindo Pharma
• Accord Healthcare
• Mylan
• Sun Pharma
• Apotex.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Lacosamide Market

Which Region Dominates the Lacosamide Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. The market for lacosamide is expanding in North America due to a number of factors, including the availability of cutting-edge medical infrastructure, rising awareness among healthcare professionals, and the prevalence of neurological illnesses. The region's lacosamide market is also growing as a result of continuous research and development initiatives meant to improve treatment alternatives for ailments like neuropathic pain and epilepsy.

Which Region is Expanding at the Fastest CAGR?

The Europe region is witnessing an increase, in the sales of reagents. The market for lacosamide is growing in Europe as a result of factors such the rise in neurological illnesses, the expansion of the healthcare system, and the growing acceptance of cutting-edge treatment alternatives. Market expansion is also aided by strict regulatory frameworks and a focus on patient safety. Europe is expected to experience sustained expansion in the lacosamide market, with an emphasis on meeting unmet medical needs.

The current report Scope analyzes Lacosamide Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Lacosamide Market

According to Cognitive Market Research, the global Lacosamide market size was estimated at USD 5815.2Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 2326.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031. The market for lacosamide is expanding rapidly in North America due to the rising incidence of neurological conditions such as epilepsy and diabetic neuropathic pain. Because of the well-established healthcare system and growing knowledge among medical experts, lacosamide is frequently recommended as a successful treatment choice. The increased prevalence of these illnesses among adults makes the adult segment particularly important for market expansion. North America's focus on patient-centered care and continuous breakthroughs in treatment alternatives will propel the lacosamide market's growth, improving outcomes for those with neurological illnesses.

Country Analysis

• According to Cognitive Market Research, the US had a major share in the Lacosamide market with a market size of USD 1835.28 million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. The demand is amplified by the rising prevalence of neurological disorders like epilepsy and neuropathic pain.
• The Canada Lacosamide market had a market share of USD 279.13 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Canada's rising coupled with increasing awareness among healthcare professionals and patients about the efficacy of lacosamide as a treatment option.
• The Mexico Lacosamide market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 211.67 million in 2024.

Europe Lacosamide Market

According to Cognitive Market Research, with a market value of USD 5815.2 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD 1744.56 million. The market for lacosamide is steadily expanding in Europe, driven by a rise in the prevalence of neurological conditions like epilepsy and neuropathic pain. Accosamide is a commonly used therapy choice because of the strong healthcare infrastructure and strict regulatory requirements in place. The pediatric market is especially significant since children with epilepsy are increasingly using lacosamide thanks to developments in pediatric medicine. Europe continues to be a key player in propelling the lacosamide market's expansion, guaranteeing improved management of neurological diseases throughout the region, with an emphasis on meeting unmet medical needs and improving patient outcomes.

• In the UK, Lacosamide sales witness an upswing due to the nation's robust robust healthcare infrastructure. 
• The France Lacosamide market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD 160.50 million in 2024.
• According to Cognitive Market Research, the Germany Lacosamide market size was valued at USD 345.42 million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. In Germany, Lacosamide sales surge due to the favorable reimbursement policies. 
• The Italy Lacosamide market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 150.03 million in 2024.
• The Russia Lacosamide market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 270.41 million in 2024.
• The Spain Lacosamide market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 143.05 million in 2024.
• The Luxembourg Lacosamide market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 54.08 million in 2024.
• The Portugal Lacosamide market is projected to witness growth at a CAGR of 3.3% during the forecast period with a market size of USD 36.64 million in 2024.
• The Greece Lacosamide market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 20.93 million in 2024.
• Rest of Europe Lacosamide market is projected to witness growth at a CAGR of 2.2% during the forecast period with a market size of USD 270.41 million in 2024.

Asia Pacific Lacosamide Market

According to Cognitive Market Research, the global Lacosamide market size was estimated at USD 5815.2Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1337.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031. The market for lacosamide is expanding significantly in the Asia Pacific area due to the increased occurrence of neurological conditions such neuropathic pain and epilepsy. The growing awareness among healthcare professionals and the advancement of healthcare infrastructure make lacosamide an essential therapy option. Because these illnesses are more common in adults, the adult group is driving market demand. In order to meet the needs of people with neurological illnesses throughout the region, Asia Pacific is well-positioned to continue driving the expansion of the lacosamide market thanks to continuous advancements in medical technology and improved access to healthcare services.

• According to Cognitive Market Research, the China Lacosamide market size was valued at USD 601.87 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Lacosamide sales surge in China due to the nation's rapid urbanization.
• The Japan Lacosamide market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 184.57 million in 2024.
• The India Lacosamide market had a market share of USD 160.50 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. The demand is augmented by India's increasing industrialization.
• The South Korea Lacosamide market is projected to witness growth at a CAGR of 6.1% during the forecast period with a market size of USD 133.75 million in 2024.
• The Australia Lacosamide market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 69.55 million in 2024.
• The South East Asia Lacosamide market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD 92.29 million in 2024.
• The Rest of Asia Pacific Lacosamide market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD 94.96 million in 2024.

South America Lacosamide Market

According to Cognitive Market Research, the global Lacosamide market size was estimated at USD 5815.2Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 290.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031. The market for lacosamide is steadily expanding in Latin America due to the rising incidence of neurological conditions like epilepsy and neuropathic pain. Despite obstacles in the healthcare system, lacosamide is becoming more and more popular as a therapeutic choice. Because these illnesses are more common in adults, the adult segment accounts for a large share of market demand. Latin America is a major contributor to the lacosamide market expansion, which benefits patient treatment for those with neurological illnesses in the region. This growth in the market is attributed to a growing emphasis on solving unmet medical requirements and expanding healthcare access.

• According to Cognitive Market Research, the Brazil Lacosamide market size was valued at USD 124.45 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Lacosamide sales flourish in Brazil due to the increasing emphasis on advanced treatment option.
• The Argentina Lacosamide market had a market share of USD 48.85 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. The demand is augmented by Argentina's commitment to healthcare access.
• The Colombia Lacosamide market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 25.88 million in 2024.
• The Peru Lacosamide market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 23.84  million in 2024.
• The Chile Lacosamide market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 20.93 million in 2024.
• The Rest of Latin America Lacosamide market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD 46.81 million in 2024.

Middle East Lacosamide Market

According to Cognitive Market Research, the global Lacosamide market size was estimated at USD 5815.2Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 116.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031. The market for lacosamide is gradually expanding in the Middle East and Africa due to the rising incidence of neurological conditions like epilepsy and neuropathic pain. Despite obstacles to access and infrastructure in healthcare, lacosamide is showing promise as a useful therapeutic choice. Because these illnesses are more common in adults, the adult group is driving market demand. The Middle East and Africa region is in a good position to positively impact patient outcomes by contributing to the growth of the lacosamide market, given its continuous efforts to address unmet medical requirements and improve healthcare services.

• According to Cognitive Market Research, the GCC Countries Lacosamide market size was valued at USD 49.78 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. Lacosamide sales flourish in the GCC Countries due to the region's strategic investments in healthcare research and advancements
• The Egypt Lacosamide market is projected to witness growth at a CAGR of 5.0% during the forecast period with a market size of USD 12.21 million in 2024.
• The South Africa Lacosamide market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD 18.38 million in 2024. Lacosamide sales flourish in the South Africa due to the region's strategic investments in healthcare research and advancements.
• The Turkey Lacosamide market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 10.00 million in 2024.
• The Nigeria Lacosamide market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 12.21 million in 2024.
• The Rest of MEA Lacosamide market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 13.72 million in 2024.

Lacosamide Market Analysis

Lacosamide Type Segment Analysis

According to Cognitive Market Research, Oral solutions held the major market share over the forecast period. The market for lacosamide is expanding as a result of the launch of oral solutions. For people who have trouble swallowing pills or capsules, oral solutions provide simple options for dosing. By reaching a wider patient base, this invention increases patient adherence to treatment plans and broadens the lacosamide market. The general accessibility and extension of lacosamide therapy is facilitated by the availability of oral solutions.

Intravenous is the fastest-growing category over the forecast period. The intravenous lacosamide formulations' acceptance and accessibility are driving the lacosamide market's expansion. When a patient is unable to take oral medication or in an emergency, intravenous administration may be chosen due to its quick beginning of action. The augmentation of administration possibilities for lacosamide augments its adaptability and effectiveness, hence bolstering its market growth and increasing its use.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Lacosamide Industry. Request a Free Sample PDF!

Lacosamide Application Segment Analysis

According to Cognitive Market Research, Adults hold a prominent market share. One of the major factors propelling the lacosamide market is the increasing incidence of neurological illnesses in adults. With the growing adult population comes a greater need for efficient therapies for ailments including diabetic neuropathic pain and epilepsy. Due to its effectiveness in treating these conditions, lacosamide is viewed as a preferable course of treatment, which has led to the market's overall increase in the adult population.

Pediatric patients is the fastest-growing category over the forecast period. Because of the rising prevalence of neuropathic pain and epilepsy in children, the pediatric market is starting to show signs of strength. Lacosamide is a useful therapy choice for pediatric populations due to its efficacy and safety profile. The use of lacosamide is anticipated to increase due to the rising focus on pediatric healthcare and developments in pediatric medicine.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manoj Phagare

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

• Worked on several market, industry & business research projects, on various models such as Syndicated, Custom, Subscriptions and Consults
• Proficient in secondary research and familiar with all paid research databases
• Proficient in primary research and handling client queries through mails and calls
• Expertise in statistical techniques used in data forecasting, possess strong grip on all aspects of market engineering & data analysis
• Expertise in checking feasibility of projects based on Request for Proposal (RFPs) of clients
• Acquainted with entire process of report writing- Title Analysis, TOC Building, Search Engine Optimization, TOC Freezing, Writing Reports, Market Engineering, Scheduling Primaries, Directory of Key Industry Participants (DKIP), Drafting “Press Articles/Summary/Report Description/Analyst Briefing” used for making marketing collaterals 
• Gained team-work skills in coordinating with the sales teams for business development and meeting needs of a variety of clients hand-in-hand with promoting sales.

Author's Conclusion